News

EIT Food- Proof of Concept co-financing instrument

Published on | 3 weeks ago

Programmes Agro-Food, Environment EIT

The EIT (European institute of innovation and technology) Food's Proof of Concept co-financing instrument provides financial support for innovative projects in the food sector. The funding is designed for researchers and start-ups that are looking to advance their original ideas and foster partnerships.

EIT Food will provide up to €100,000 in grant funding, covering 100% of the project costs for successful applications. EIT Food will then establish a service agreement with your corporate client, invoicing them for 60% of the project costs (up to €60,000). The cut-off date is at each last day of the month with the final deadline on the 30th of November. 

You can find all details on this website

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1683 articles available search in articles 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.